Applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.
Learn more about our leading ProTide candidates and our clinical studies
Acelarin (NUC-1031) Studies
Acelarin is being evaluated in several clinical studies, including a Phase III registrational study for patients with biliary tract cancer.
NUC-3373 is being investigated in two clinical studies including a Phase Ib study in patients with advanced colorectal cancer.
NUC-7738, is being investigated in a Phase I study for patients with advanced solid tumours.